Neumora Therapeutics (NMRA) Stock Forecast, Price Target & Predictions

NMRA Stock Forecast

Neumora Therapeutics stock forecast is as follows: an average price target of $21.50 (represents a 98.16% upside from NMRA’s last price of $10.85) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

NMRA Price Target

The average price target for Neumora Therapeutics (NMRA) is $21.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $23.00 to $20.00. This represents a potential 98.16% upside from NMRA's last price of $10.85.

NMRA Analyst Ratings

Buy

According to 4 Wall Street analysts, Neumora Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NMRA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Neumora Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 22, 2024	Ami Fadia	Needham	$23.00	$11.28	103.90%	111.98%
Jul 08, 2024	Graig Suvannavejh	Mizuho Securities	$20.00	$10.25	95.12%	84.33%
Jun 17, 2024	Brian Abrahams	RBC Capital	$29.00	$9.71	198.66%	167.28%
Mar 13, 2024	Brian Abrahams	RBC Capital	$31.00	$14.81	109.32%	185.71%
Oct 10, 2023	Brian Abrahams	RBC Capital	$24.00	$10.91	119.98%	121.20%
Oct 10, 2023	Paul Matteis	Stifel Nicolaus	$26.00	$10.91	138.31%	139.63%

The latest Neumora Therapeutics stock forecast, released on Jul 22, 2024 by Ami Fadia from Needham, set a price target of $23.00, which represents a 103.90% increase from the stock price at the time of the forecast ($11.28), and a 111.98% increase from NMRA last price ($10.85).

Neumora Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$25.75
Last Closing Price	$10.85	$10.85	$10.85
Upside/Downside	-100.00%	-100.00%	137.33%

In the current month, the average price target of Neumora Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Neumora Therapeutics's last price of $10.85. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	H.C. Wainwright		Buy	Initialise
Jul 22, 2024	Needham		Buy	Initialise
Jun 17, 2024	RBC Capital	Outperform	Outperform	Hold
Oct 10, 2023	RBC Capital		Outperform	Initialise
Oct 10, 2023	William Blair		Outperform	Initialise

Neumora Therapeutics's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company Initialise its NMRA rating from "null" to "Buy".

Neumora Therapeutics Financial Forecast

Neumora Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
# Analysts	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Neumora Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NMRA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Neumora Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

undefined analysts predict NMRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Neumora Therapeutics's previous annual EBITDA (undefined) of $NaN.

Neumora Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-
Avg Forecast	$-68.22M	$-69.81M	$-71.01M	$-71.81M	$-70.98M	$-62.32M	$-59.14M
High Forecast	$-68.22M	$-69.81M	$-71.01M	$-68.62M	$-70.98M	$-62.32M	$-59.14M
Low Forecast	$-68.22M	$-69.81M	$-71.01M	$-75.00M	$-72.52M	$-62.32M	$-59.14M
Surprise %	-	-	-	-	-	-	-

Neumora Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NMRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Neumora Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-

Neumora Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NMRA last annual SG&A of $NaN (undefined).

Neumora Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-
Avg Forecast	$-0.43	$-0.44	$-0.45	$-0.45	$-0.44	$-0.39	$-0.37
High Forecast	$-0.43	$-0.44	$-0.45	$-0.43	$-0.44	$-0.39	$-0.37
Low Forecast	$-0.43	$-0.44	$-0.45	$-0.47	$-0.45	$-0.39	$-0.37
Surprise %	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Neumora Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NMRA previous annual EPS of $NaN (undefined).

NMRA Forecast FAQ

Is Neumora Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Neumora Therapeutics (NMRA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of NMRA's total ratings.

What is NMRA's price target?

Neumora Therapeutics (NMRA) average price target is $21.5 with a range of $20 to $23, implying a 98.16% from its last price of $10.85. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Neumora Therapeutics stock go up soon?

According to Wall Street analysts' prediction for NMRA stock, the company can go up by 98.16% (from the last price of $10.85 to the average price target of $21.5), up by 111.98% based on the highest stock price target, and up by 84.33% based on the lowest stock price target.

Can Neumora Therapeutics stock reach $20?

NMRA's average twelve months analyst stock price target of $21.5 supports the claim that Neumora Therapeutics can reach $20 in the near future.

What are Neumora Therapeutics's analysts' financial forecasts?

Neumora Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-192M (high $-192M, low $-194M), average SG&A $0 (high $0, low $0), and average EPS is $-1.207 (high $-1.207, low $-1.217). NMRA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-281M (high $-278M, low $-284M), average SG&A $0 (high $0, low $0), and average EPS is $-1.76 (high $-1.74, low $-1.78).